Overview

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is changing (improving), after initiating various doses of Paliperidone ER on schizophrenia patients.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Johnson & Johnson
Treatments:
Paliperidone Palmitate